List view / Grid view
Recent advancements in targeted therapies and immunotherapies are transforming lung cancer treatment. Discover how these innovations are improving outcomes and providing hope for patients.
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
A study has discovered the mechanism behind NSCLC resistance to chemotherapy, which could improve treatment strategies for the condition.
